Servicios Personalizados
Revista
Articulo
Links relacionados
Compartir
Revista Uruguaya de Cardiología
versión impresa ISSN 0797-0048versión On-line ISSN 1688-0420
Resumen
FRIPP, Gabriel y BAZZINO, Oscar. Antithrombotics in biological valve prostheses: what is the best way forward?. Rev.Urug.Cardiol. [online]. 2023, vol.38, n.1, e404. Epub 01-Jun-2023. ISSN 0797-0048. https://doi.org/10.29277/cardio.38.1.6.
Heart valve disease is a very common condition in the general population and a considerable percentage of these patients require interventional treatment for their valve disease to mitigate its natural evolution. In this context, the use of biological prosthetic valves for their treatment has now increased, and with this, the dilemma of antithrombotic management in these patients arises, in terms of prevention of thromboembolism and hemorrhagic events. What is the most effective and safe drug in the early postoperative period? What antithrombotics can we use in the late postoperative period? What strategy do we follow when the patient presents other indications for anticoagulation? The objective of this review is to assess the current evidence regarding antithrombotic treatment in patients with biological prosthetic valves with and without additional indications for anticoagulation.
Palabras clave : biological prosthetic valve; antithrombotics; direct anticoagulants; warfarin; acetylsalicylic acid.